Literature DB >> 30418657

Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool.

Paul W Sperduto1, Brian J Deegan2, Jing Li2, Krishan R Jethwa3, Paul D Brown3, Natalie Lockney4, Kathryn Beal4, Nitesh G Rana5, Albert Attia5, Chia-Lin Tseng6, Arjun Sahgal6, Ryan Shanley7, William A Sperduto8, Emil Lou8, Amir Zahra9, John M Buatti9, James B Yu10, Veronica Chiang11, Jason K Molitoris12, Laura Masucci13, David Roberge13, Diana D Shi14, Helen A Shih14, Adam Olson15, John P Kirkpatrick15, Steve Braunstein16, Penny Sneed16, Minesh P Mehta17.   

Abstract

Background: Brain metastases are a common complication of renal cell carcinoma (RCC). Our group previously published the Renal Graded Prognostic Assessment (GPA) tool. In our prior RCC study (n = 286, 1985-2005), we found marked heterogeneity and variation in outcomes. In our recent update in a larger, more contemporary cohort, we identified additional significant prognostic factors. The purpose of this study is to update the original Renal-GPA based on the newly identified prognostic factors.
Methods: A multi-institutional retrospective institutional review board-approved database of 711 RCC patients with new brain metastases diagnosed from January 1, 2006 to December 31, 2015 was created. Clinical parameters and treatment were correlated with survival. A revised Renal GPA index was designed by weighting the most significant factors in proportion to their hazard ratios and assigning scores such that the patients with the best and worst prognoses would have a GPA of 4.0 and 0.0, respectively.
Results: The 4 most significant factors were Karnofsky performance status, number of brain metastases, extracranial metastases, and hemoglobin. The overall median survival was 12 months. Median survival for GPA groups 0-1.0, 1.5-2.0, 2.5-3, and 3.5-4.0 (% n = 25, 27, 30 and 17) was 4, 12, 17, and 35 months, respectively.
Conclusion: The updated Renal GPA is a user-friendly tool that will help clinicians and patients better understand prognosis, individualize clinical decision making and treatment selection, provide a means to compare retrospective literature, and provide more robust stratification of future clinical trials in this heterogeneous population. To simplify use of this tool in daily practice, a free online application is available at brainmetgpa.com.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30418657      PMCID: PMC6231200          DOI: 10.1093/neuonc/noy099

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  16 in total

1.  Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases.

Authors:  Paul W Sperduto; Norbert Kased; David Roberge; Zhiyuan Xu; Ryan Shanley; Xianghua Luo; Penny K Sneed; Samuel T Chao; Robert J Weil; John Suh; Amit Bhatt; Ashley W Jensen; Paul D Brown; Helen A Shih; John Kirkpatrick; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan P S Knisely; Christina Maria Sperduto; Nancy Lin; Minesh Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-15       Impact factor: 7.038

Review 2.  Systemic Therapy for Metastatic Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Robert J Motzer
Journal:  N Engl J Med       Date:  2017-01-26       Impact factor: 91.245

3.  Recent developments in second and third line therapy of metastatic renal cell carcinoma.

Authors:  Maria Giuseppa Vitale; Giacomo Cartenì
Journal:  Expert Rev Anticancer Ther       Date:  2016-03-31       Impact factor: 4.512

4.  Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases.

Authors:  Paul W Sperduto; Norbert Kased; David Roberge; Zhiyuan Xu; Ryan Shanley; Xianghua Luo; Penny K Sneed; Samuel T Chao; Robert J Weil; John Suh; Amit Bhatt; Ashley W Jensen; Paul D Brown; Helen A Shih; John Kirkpatrick; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan P S Knisely; Christina Maria Sperduto; Nancy Lin; Minesh Mehta
Journal:  J Clin Oncol       Date:  2011-12-27       Impact factor: 44.544

5.  The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases.

Authors:  Paul W Sperduto; T Jonathan Yang; Kathryn Beal; Hubert Pan; Paul D Brown; Ananta Bangdiwala; Ryan Shanley; Norman Yeh; Laurie E Gaspar; Steve Braunstein; Penny Sneed; John Boyle; John P Kirkpatrick; Kimberley S Mak; Helen A Shih; Alex Engelman; David Roberge; Nils D Arvold; Brian Alexander; Mark M Awad; Joseph Contessa; Veronica Chiang; John Hardie; Daniel Ma; Emil Lou; William Sperduto; Minesh P Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-06-14       Impact factor: 7.038

6.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

Authors:  Robert J Motzer; Jennifer Bacik; Barbara A Murphy; Paul Russo; Madhu Mazumdar
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

7.  The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.

Authors:  Paul W Sperduto; Wen Jiang; Paul D Brown; Steve Braunstein; Penny Sneed; Daniel A Wattson; Helen A Shih; Ananta Bangdiwala; Ryan Shanley; Natalie A Lockney; Kathryn Beal; Emil Lou; Thomas Amatruda; William A Sperduto; John P Kirkpatrick; Norman Yeh; Laurie E Gaspar; Jason K Molitoris; Laura Masucci; David Roberge; James Yu; Veronica Chiang; Minesh Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-03-29       Impact factor: 7.038

8.  Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients.

Authors:  Paul W Sperduto; Samuel T Chao; Penny K Sneed; Xianghua Luo; John Suh; David Roberge; Amit Bhatt; Ashley W Jensen; Paul D Brown; Helen Shih; John Kirkpatrick; Amanda Schwer; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan Knisely; Christina Maria Sperduto; Minesh Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-11-26       Impact factor: 7.038

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.

Authors:  Paula Mulvenna; Matthew Nankivell; Rachael Barton; Corinne Faivre-Finn; Paula Wilson; Elaine McColl; Barbara Moore; Iona Brisbane; David Ardron; Tanya Holt; Sally Morgan; Caroline Lee; Kathryn Waite; Neil Bayman; Cheryl Pugh; Benjamin Sydes; Richard Stephens; Mahesh K Parmar; Ruth E Langley
Journal:  Lancet       Date:  2016-09-04       Impact factor: 79.321

View more
  17 in total

1.  Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?

Authors:  Paul W Sperduto; Penny Fang; Jing Li; William Breen; Paul D Brown; Daniel Cagney; Ayal Aizer; James Yu; Veronica Chiang; Supriya Jain; Laurie E Gaspar; Sten Myrehaug; Arjun Sahgal; Steve Braunstein; Penny Sneed; Brent Cameron; Albert Attia; Jason Molitoris; Cheng-Chia Wu; Tony J C Wang; Natalie Lockney; Kathryn Beal; Jessica Parkhurst; John M Buatti; Ryan Shanley; Emil Lou; Daniel D Tandberg; John P Kirkpatrick; Diana Shi; Helen A Shih; Michael Chuong; Hirotake Saito; Hidefumi Aoyama; Laura Masucci; David Roberge; Minesh P Mehta
Journal:  Transl Res       Date:  2019-02-27       Impact factor: 7.012

2.  Population-based estimates of survival among elderly patients with brain metastases.

Authors:  Nayan Lamba; Rachel Brigell Kearney; Paul J Catalano; Michael J Hassett; Patrick Y Wen; Daphne A Haas-Kogan; Ayal A Aizer
Journal:  Neuro Oncol       Date:  2021-04-12       Impact factor: 12.300

3.  Metastatic renal cell carcinoma to the brain: optimizing patient selection for gamma knife radiosurgery.

Authors:  U Harmenberg; M Lindskog; G Sinclair; M Stenman; H Benmakhlouf; P Wersäll; P Johnstone; M A Hatiboglu; J Mayer-da-Silva
Journal:  Acta Neurochir (Wien)       Date:  2020-09-09       Impact factor: 2.216

4.  Validation of a Graded Prognostic Model in Patients With Brain Metastases Treated With Whole-brain Radiotherapy Instead of Radiosurgery.

Authors:  Carsten Nieder; Bård Mannsåker; Rosalba Yobuta
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

5.  Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient.

Authors:  Paul W Sperduto; Shane Mesko; Jing Li; Daniel Cagney; Ayal Aizer; Nancy U Lin; Eric Nesbit; Tim J Kruser; Jason Chan; Steve Braunstein; Jessica Lee; John P Kirkpatrick; Will Breen; Paul D Brown; Diana Shi; Helen A Shih; Hany Soliman; Arjun Sahgal; Ryan Shanley; William A Sperduto; Emil Lou; Ashlyn Everett; Drexell H Boggs; Laura Masucci; David Roberge; Jill Remick; Kristin Plichta; John M Buatti; Supriya Jain; Laurie E Gaspar; Cheng-Chia Wu; Tony J C Wang; John Bryant; Michael Chuong; Yi An; Veronica Chiang; Toshimichi Nakano; Hidefumi Aoyama; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2020-09-15       Impact factor: 44.544

6.  Type and timing of systemic therapy use predict overall survival for patients with brain metastases treated with radiation therapy.

Authors:  Kevin Yijun Fan; Nafisha Lalani; Nathalie LeVasseur; Andra Krauze; Fred Hsu; Lovedeep Gondara; Kaylie Willemsma; Alan McVey Nichol
Journal:  J Neurooncol       Date:  2020-11-18       Impact factor: 4.130

7.  Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today.

Authors:  Paul W Sperduto; Shane Mesko; Jing Li; Daniel Cagney; Ayal Aizer; Nancy U Lin; Eric Nesbit; Tim J Kruser; Jason Chan; Steve Braunstein; Jessica Lee; John P Kirkpatrick; Will Breen; Paul D Brown; Diana Shi; Helen A Shih; Hany Soliman; Arjun Sahgal; Ryan Shanley; William Sperduto; Emil Lou; Ashlyn Everett; Drexell Hunter Boggs; Laura Masucci; David Roberge; Jill Remick; Kristin Plichta; John M Buatti; Supriya Jain; Laurie E Gaspar; Cheng-Chia Wu; Tony J C Wang; John Bryant; Michael Chuong; James Yu; Veronica Chiang; Toshimichi Nakano; Hidefumi Aoyama; Minesh P Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-02-19       Impact factor: 7.038

8.  The Clinical Frailty Scale as useful tool in patients with brain metastases.

Authors:  Johannes Kerschbaumer; Aleksandrs Krigers; Matthias Demetz; Daniel Pinggera; Julia Klingenschmid; Nadine Pichler; Claudius Thomé; Christian F Freyschlag
Journal:  J Neurooncol       Date:  2022-04-13       Impact factor: 4.506

9.  Neurosurgical resection for locally recurrent brain metastasis.

Authors:  Alexander F C Hulsbergen; Abdullah M Abunimer; Fidelia Ida; Vasileios K Kavouridis; Logan D Cho; Ishaan A Tewarie; Rania A Mekary; Philippe Schucht; John G Phillips; Joost J C Verhoeff; Marike L D Broekman; Timothy R Smith
Journal:  Neuro Oncol       Date:  2021-12-01       Impact factor: 13.029

10.  Validation of the updated renal graded prognostic assessment (GPA) for patients with renal cancer brain metastases treated with gamma knife radiosurgery.

Authors:  Laurens V Beerepoot; Patrick E J Hanssens; Niels J van Ruitenbeek; Vincent K Y Ho; Hans M Westgeest
Journal:  J Neurooncol       Date:  2021-06-25       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.